STOCK TITAN

Moderna Inc - MRNA STOCK NEWS

Welcome to our dedicated news page for Moderna (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Moderna's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Moderna's position in the market.

Rhea-AI Summary
Moderna's updated COVID-19 vaccine shows significant increase in neutralizing antibodies against BA.2.86 variant
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
clinical trial covid-19
-
Rhea-AI Summary
Moderna to host Investor Event - R&D Day and Business Updates on September 13, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
conferences
-
News
Rhea-AI Summary
CARsgen Therapeutics Holdings Limited announces its 2023 Interim Results with several positive developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.65%
Tags
none
Rhea-AI Summary
Moderna announces updated COVID-19 vaccine targeting EG.5 and FL 1.5.1 variants. Preliminary clinical trial data show significant boost in neutralizing antibodies. Vaccine expected to be available in the coming weeks for fall vaccination season.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.35%
Tags
clinical trial covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
none
-
Rhea-AI Summary
Moderna, Inc. (MRNA) reported Q2 2023 revenues of $0.3 billion, with a net loss of $1.4 billion and loss per share of $3.62. The company expects 2023 COVID-19 vaccine sales of $6-8 billion, pending U.S. vaccination rates. Moderna submitted its RSV vaccine for potential 2024 launch and began Phase 3 trial of mRNA-4157 in combination with Keytruda for high-risk melanoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
earnings
Rhea-AI Summary
Merck and Moderna initiate Phase 3 trial for V940 (mRNA-4157) in combination with KEYTRUDA as adjuvant treatment for melanoma
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
clinical trial
-
Rhea-AI Summary
Merck and Moderna initiate Phase 3 trial for V940 (mRNA-4157) in combination with KEYTRUDA as adjuvant treatment for melanoma
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
clinical trial
-
Rhea-AI Summary
Moderna, Inc. (Nasdaq: MRNA) to report Q2 2023 financial results and corporate update on August 3, 2023. Live webcast available on the Moderna website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
none
Moderna Inc

Nasdaq:MRNA

MRNA Rankings

MRNA Stock Data

40.80B
344.83M
9.63%
71.82%
5.81%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Cambridge

About MRNA

moderna is pioneering messenger rna therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. this breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions. moderna has developed a broad intellectual property estate including more than 200 patent applications with more than 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions. the company plans to develop and commercialize its innovative mrna drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutics areas in order to rapidly deliver this innovation to patients. based in cambridge, massachusetts, moderna is privately held and was founded in 2010 by flagship venturelabs in association with leading scientists from boston children’s hospital a